RxDoctor Payments Data
★ My doctorsLook up a doctor →

Hope Achoronye

Psychiatric/Mental Health · Washington, DCNPI 1891460895

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.3% of the total across 177 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,472, 8.2 times the $180 reported in 2022. Among psychiatric/mental health clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,951in general payments, 2019–2025

Across 177 payments — averaging $22.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$862
  • Johnson & Johnson$804
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$554
  • Teva Pharmaceuticals USA, Inc.$462
  • Neurocrine Biosciences, Inc.$369
  • AbbVie$262
  • plus $637 from 6 others

What the payments were for

  • Food & beverage$3,76495%
  • Education$1885%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Otsuka America Pharmaceutical, Inc.38$862
Johnson & Johnson29$804
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)26$554
Teva Pharmaceuticals USA, Inc.28$462
Neurocrine Biosciences, Inc.16$369
AbbVie13$262
Vanda Pharmaceuticals Inc.9$260
Alkermes, Inc.9$172
E.r. Squibb & Sons, L.L.C.4$86
Indivior Inc.2$63
Lundbeck LLC2$33
Corium, LLC1$23

How this compares

$3,951 in reported general payments places this provider in the 95th percentile of 137 psychiatric/mental health providers in District of Columbia.

See all psychiatric/mental health providers in District of Columbia →

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole31$77,787
Invega SustennaPaliperidone Palmitate15$37,645
RexultiBrexpiprazole11$16,265
Clozapine20$709
Quetiapine Fumarate53$618
Olanzapine14$466
Hydroxyzine Pamoate12$92
Escitalopram Oxalate13$57
Trazodone Hcl17$39
Benztropine Mesylate13$34
Sertraline Hcl20$30

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$862$94,05242 claims
Johnson & JohnsonInvega Sustenna$804$37,64515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 137 psychiatric/mental health providers in District of Columbia.

Other psychiatric/mental health in Washington

See the full list for District of Columbia →

Where these figures come from

Is this you, or does something look wrong? →